Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Factor VIII deficiency+1

Recruiting

Registered drugNo placebo

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Efanesoctocog Alfa

Contact Research Centre

Factor VIII deficiency

Recruiting

Registered drugNo placebo

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Emicizumab

Contact Research Centre

Factor VIII deficiency

Recruiting

Registered drugNo placebo

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Ro7589655

Contact Research Centre

Factor VIII deficiency+1

Recruiting

InvestigationalNo placebo

A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

InvestigationalNo placebo

France

Participants:18–64 years
Substances:Fidanacogene Elaparvovec

Contact Research Centre

Factor VIII deficiency

Recruiting

Registered drugNo placebo

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Registered drugNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Emicizumab

Contact Research Centre

Factor VIII deficiency

Recruiting

Registered drugNo placebo

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Efanesoctocog Alfa

Contact Research Centre

Factor VIII deficiency+3

Recruiting

InvestigationalNo placebo

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Concizumab

Contact Research Centre

Factor VIII deficiency

Recruiting

Registered drugNo placebo

Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Emicizumab

Contact Research Centre

Factor VIII deficiency

Recruiting

InvestigationalNo placebo

Study on the Safety and Effects of NXT007 for Patients with Severe or Moderate Hemophilia A

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Ro7589655

Contact Research Centre

Factor VIII deficiency+1

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Marstacimab

Contact Research Centre

Factor VIII deficiency+1

Recruiting

InvestigationalNo placebo

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Austria

Participants:0–17 years
Substances:Marstacimab

Contact Research Centre

Factor VIII deficiency

Recruiting

Registered drugNo placebo

Study on the Use of Simoctocog Alfa and Emicizumab for Surgery in Patients with Severe Hemophilia A

Registered drugNo placebo

Croatia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Simoctocog Alfa

Contact Research Centre

Find therapies in clinical trials near you

25 trials match your criteria

Factor VIII deficiency+1

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Factor VIII deficiency

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Factor VIII deficiency

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Factor VIII deficiency+1

A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

Factor VIII deficiency

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Factor VIII deficiency

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Factor VIII deficiency+3

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

Factor VIII deficiency

Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

Factor VIII deficiency

Study on the Safety and Effects of NXT007 for Patients with Severe or Moderate Hemophilia A

Factor VIII deficiency+1

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

Factor VIII deficiency+1

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

Factor VIII deficiency

Study on the Use of Simoctocog Alfa and Emicizumab for Surgery in Patients with Severe Hemophilia A

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.